Sign up by: 25 November 2023
The main goal of the S-citAD study is to assess the safety and efficacy of escitalopram (a drug) in combination with psychosocial intervention as a treatment for agitation in patients with Alzheimer's disease. It will also look at the predictors of relapse and response duration, in patients with Alzheimer's disease with agitation who improve with psychosocial intervention, as well as those who do not improve with psychosocial intervention. This 24-week trial (12 weeks treatment; 12 weeks follow-up) enrolls participants from real world settings such as outpatient and assisted living facilities.
Study Sponsor: This study is funded by the National Institute on Aging (NIA)/ Johns Hopkins University.
Currently Enrolling: Individuals living in Whitby and the surrounding areas including the greater Toronto area
Location: In-person (Required at Ontario Shores Centre for Mental Health Sciences*) + Phone (Optional) + Internet (Optional)
*The majority of the visits during this study will be completed via phone or video calls. However, participants will be required to come to Ontario Shores Centre for Mental Health Sciences for 2 or 6 visits during the 15-week treatment period.
How Often: Monthly
Compensation: Yes (Participants will receive payment of $25 per visit*)
*This applies to the first two visits, as well as Week 3, Week 6, Week 9 and Week 12. For in-person visits, participants will receive payment at the end of the visit. For telephone/video contacts, participants will be emailed an electronic gift card/cheque by regular mail (Canada Post).
Contact: Elaina Niciforos, Lead Study Co-ordinator
905-430-4055 Ext. 6139
905-430-4055 Ext. 6423